Diffusion Pharmaceuticals Inc. (DFFN)

$7.9

-0.03 (-0.38%)
Rating:
Recommendation:
Neutral
Symbol DFFN
Price $7.9
Beta 1.670
Volume Avg. 0.09M
Market Cap 16.105M
Shares () -
52 Week Range 5.1-43.0
1y Target Est -
DCF Unlevered DFFN DCF ->
DCF Levered DFFN LDCF ->
ROE -11833302.21% Strong Sell
ROA -13554281.88% Strong Sell
Operating Margin -
Debt / Equity 9.65% Neutral
P/E -
P/B 0.53 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest DFFN news


Mr. David G. Kalergis M.B.A., MBA, J.D.
Healthcare
Biotechnology
NASDAQ Capital Market

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.